PDS Biotechnology Corporation

Greetings. Welcome to PDS Biotech Second Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce Mike Moyer with Lakeside Advisors. Thank you. You may begin.

Thank you, operator. Good morning, everyone, and welcome to PDS Biotech's second quarter 2025 results and clinical programs update call. I'm joined on the call today by the following members of the company's management team. Dr. Frank Badu-Addo, Chief Executive Officer, Dr. Kirk Shepard, Chief Medical Officer, and Lars Bosgaard, Chief Financial Officer. Dr. Badu-Addo will begin with an overview of the company's recent progress in its clinical development program, Mr. Boesgaard will then review the financial results for the quarter ended June 30, 2025, and Dr. Shepherd will join the call to help address questions from covering analysts during the Q&A. As a reminder, during this call, we will be making forward-looking statements which are subject to various risks and uncertainties that could cause our actual results to differ materially from these statements. Any such statements should be considered in conjunction with cautionary statements in our press releases and risk factors discussed in our filings with the SEC. including our quarterly reports on Form 10-Q and annual report on Form 10-K, and cautionary statements made during this call. We assume no obligation to update any of these forward-looking statements or information.

Now I'd like to turn the call over to Dr. Badou Addo. Frank? Thank you, Mike. Dr. Badou Addo, you're- And good morning. Thank you.